Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 15, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

PSA measurement following prostatectomy: an unexpected error.

Jean-Luc Descotes1, Didier Legeais, Anne-Sophie Gauchez

  • 1Service de Chirurgie Urologique et de Transplantation Rénale, CHU de Grenoble, 38043 Grenoble 9, France.

Anticancer Research
|May 1, 2007
PubMed
Summary

Following prostate cancer surgery, a residual prostate-specific antigen (PSA) level was initially thought to indicate recurrence. However, this study highlights the limitations of PSA testing and the need for comprehensive interpretation with other prognostic factors.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Partial Nephrectomy Versus Thermal Ablation for Cystic Renal Tumors: A Registry-Based, Propensity Score Matched Analysis (UroCCR n°177).

Cardiovascular and interventional radiology·2026
Same author

Evaluation of the effect of virtual reality hypnosis on pain through attentional diversion during prostate biopsies under local anesthesia (HYPNOSURG-VR): a study protocol.

International journal of surgery protocols·2025
Same author

Leveraging knowledge for explainable AI in personalized cancer treatment: challenges and future directions.

Frontiers in digital health·2025
Same author

Chemotherapy use in triplet approach for metastatic hormone-sensitive prostate cancer: French practice survey and expert opinion.

The French journal of urology·2025
Same author

Racial differences in kidney cancer histology and outcome: A nationwide study from the UroCCR Cohort.

Cancer·2025
Same author

Functional and urodynamics outcomes after robot-assisted cystoprostatectomy with intracorporeal neobladder: Impact of the learning curve.

The French journal of urology·2025

Area of Science:

  • Oncology
  • Biochemistry
  • Urology

Background:

  • Radical prostatectomy is a primary treatment for prostate adenocarcinoma.
  • Monitoring prostate-specific antigen (PSA) levels is crucial for detecting cancer recurrence post-surgery.

Observation:

  • An unusual observation occurred during the follow-up of a patient treated for prostate adenocarcinoma.
  • A persistently detectable PSA level was noted after radical prostatectomy.

Findings:

  • The residual PSA level was initially interpreted as a reliable indicator of cancer relapse.
  • The reliability of PSA assays has inherent limitations and requires careful consideration.
  • PSA results should be integrated with other tumor prognostic information for accurate interpretation.

More Related Videos

Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

Related Experiment Videos

Last Updated: Jul 15, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

Implications:

  • Relying solely on PSA levels for relapse detection can be misleading.
  • Further biological verification may be necessary to confirm PSA assay findings.
  • A multi-faceted approach is essential for accurate post-treatment cancer surveillance.